Form D · Biotechnology
NERx Biosciences, Inc.
Indianapolis, IN · CIK 0001764454
Offering snapshot reported Nov 5, 2021 · SEC filing
- Reported sold
- $200K Offering amount: $400K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2021 | Initial | $200,000 | No comparison | 3 | SEC filing |
| Jan 11, 2019 | Initial | $850,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-420048
Source: Form D, filed Nov 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicholas Ball | Director, Executive |
| Trent Carrier | Director |
| Katherine Pawelczak | Director, Executive |
| John J. Turchi | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
212 W 10 Th St, Suite A480
Indianapolis, IN, 46202
Indianapolis, IN, 46202